Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Circadian Rhythm of Copeptin (Co-Rhythm)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02604875
Recruitment Status : Completed
First Posted : November 16, 2015
Last Update Posted : August 15, 2016
Sponsor:
Information provided by (Responsible Party):
University Hospital, Basel, Switzerland

Brief Summary:
The circadian rhythm of copeptin will be examined in healthy subjects.

Condition or disease Intervention/treatment
Circadian Rhythm Copeptin Blood Levels Other: observation

Detailed Description:
In 18 healthy volunteers the circadian rhythm of copeptin will be examined by withdrawing blood samples for copeptin levels every 30 minutes for 24 hours.

Layout table for study information
Study Type : Observational
Actual Enrollment : 18 participants
Time Perspective: Prospective
Official Title: The Circadian Rhythm of Copeptin
Study Start Date : November 2015
Actual Primary Completion Date : April 2016
Actual Study Completion Date : April 2016

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
observational
Blood samples will be taken for measuring copeptin levels in healthy subjects.
Other: observation
blood sampling during 24 hours




Primary Outcome Measures :
  1. measurement of copeptin values in mmol/l within 24 hours to assess the amount of release in a day curve. [ Time Frame: 24 hours ]
    The primary outcome measure is to compare the copeptin concentration in the early afternoon and the early morning by blood sampling at different time points. Evaluation of the question if there is a circadian rhythm in the copeptin release.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
healthy subjects
Criteria

Inclusion Criteria:

  • healthy subjects

Exclusion Criteria:

  • acute illness
  • chronic illness
  • pregnancy
  • Anemia defined as Hb < 30g/l

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02604875


Locations
Layout table for location information
Switzerland
University Hospital Basel
Basel, Basel-Stadt, Switzerland, 4031
Sponsors and Collaborators
University Hospital, Basel, Switzerland
Investigators
Layout table for investigator information
Principal Investigator: Mirjam Christ-Crain, MD, Prof. University Hospital, Basel, Switzerland
Layout table for additonal information
Responsible Party: University Hospital, Basel, Switzerland
ClinicalTrials.gov Identifier: NCT02604875    
Other Study ID Numbers: EKNZ 2015-266
First Posted: November 16, 2015    Key Record Dates
Last Update Posted: August 15, 2016
Last Verified: August 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Insipidus
Kidney Diseases
Urologic Diseases
Pituitary Diseases
Endocrine System Diseases